drugset / Trial / NCT04528056

Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

NCT04528056

Phase 1/2 Unknown 80 enrolled RenJi Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.

Timeline

Start
2020-08-01
Primary completion
2021-12-31
Completion
2022-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambrisentan Small molecule
Subject Sulfasalazine Small molecule